Navigation Links
Bioheart Makes Breakthrough in Critical Limb Ischemia Therapy with Stem Cells Obtained from Fat Tissue
Date:12/21/2009

GI 1200 System which separates out and collects adipose stem cells.

The CE mark approved system which is distributed by Bioheart under an exclusive license from Tissue Genesis, Inc., accepts adipose tissue from the same device used for liposuctioning the tissue from the patient. The compact desktop unit readily fits into any clinical environment and uses preconfigured disposables for quick and easy operation.

Editor's notes:

ABOUT BIOHEART, INC

Bioheart, Inc. is committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and cardiovascular diseases. Its goals are to improve a patient's quality of life and reduce health care costs and hospitalizations.

Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Its lead product candidate, MyoCell(R), is an innovative clinical muscle-derived stem cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients.

The Company's pipeline includes multiple product candidates for the treatment of heart damage, including Bioheart Acute Cell Therapy, an autologous, adipose tissue-derived stem cell treatment for acute heart damage, and MyoCell(R) SDF-1, a therapy utilizing autologous cells that are genetically modified to express additional potentially therapeutic growth proteins.

For more information on Bioheart, visit www.bioheartinc.com.

Forward-Looking Statements:


'/>"/>
SOURCE Bioheart, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Bioheart Inc. to Participate in the 2009 World Stem Cell Summit on September 23rd
2. Bioheart Strengthens Executive Team in Order to Accelerate Business Plan and Enhance Its Position in the Cardiovascular Stem Cell Therapy Industry
3. United States FDA Clears the REGEN Trial to Test Biohearts Combination Gene and Stem Cell Therapy in Heart Failure Patients
4. Bioheart, Inc. Announces Additional Funding Support
5. Bioheart, Inc. to Present at Red Chip Investor Conference in New York
6. Bioheart, Inc., Announces Letter of Intent to Acquire MEDICALGORITHMICS, Ltd.
7. Bioheart, Inc. Announces Financial Results for Second Quarter 2008
8. Bioheart, Inc. Announces Results of Annual Meeting
9. Bioheart, Inc., Announces Management Change
10. Bioheart, Inc. to Introduce At-Home Heart Failure Monitor for Congestive Heart Failure Patients
11. Bioheart, Inc., Board Appoints Howard J. Leonhardt Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... ANGELES , May 21, 2015  CytRx ... and development company specializing in oncology, today announced ... clinical trial with aldoxorubicin for the treatment of ... brain cancer.  The open-label, multisite trial is designed ... aldoxorubicin in patients whose tumors have progressed following ...
(Date:5/21/2015)... May 21, 2015 Tunnell Consulting, ... the firm as senior statistician and Principal, a position ... experience in the management and analysis of complex and ... chemical industries. , “We’re delighted to have Julia join ... data analytics,” said Dr. Philippe Cini, Group Vice President ...
(Date:5/20/2015)... MECHANICSBURG, Pa. , May 20, 2015 /PRNewswire/ ... announced that the Federal Trade Commission granted early ... (HSR) Antitrust Improvements Act of 1976, as amended, ... by MJ Acquisition Corporation, a joint venture that ... XII, L.P. As previously announced, MJ ...
(Date:5/20/2015)... 20, 2015  Haemonetics Corporation (NYSE: HAE ) ... CEO, will present at The Jefferies 2015 Global Healthcare ... June 1 st , 2015 at 8:30am Eastern time.  ... presentation live via webcast at: http://wsw.com/webcast/jeff88/hae ... HAE ) is a global healthcare company dedicated to ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2Select Medical Corporation's Proposed Acquisition of Concentra Inc. through Joint Venture with Welsh Carson Receives Antitrust Clearance 2
... Surface Logix today announced positive,results in ... SLx-4090 in,dyslipidemia (high cholesterol and triglyceride levels ... 2a study in 24,patients with dyslipidemia demonstrated ... triglycerides and LDL-cholesterol,and was well tolerated. The ...
... Edwards Lifesciences,Corporation (NYSE: EW ), the world leader ... has received conditional approval from the U.S.,Food and Drug ... pivotal,clinical trial of the Edwards SAPIEN transcatheter aortic heart ... transapical,delivery system to the trial, and also granted permission ...
... ) consolidated net earnings for the quarter ended December ... diluted share compared,with $18.7 million or $.47 per diluted ... six months ended December 31, 2007, Techne,s consolidated,net earnings ... share,compared with $38.3 million or $0.97 per diluted share ...
Cached Biology Technology:Surface Logix Achieves Objectives With SLx-4090 in Phase 2a Clinical Trial 2Surface Logix Achieves Objectives With SLx-4090 in Phase 2a Clinical Trial 3Surface Logix Achieves Objectives With SLx-4090 in Phase 2a Clinical Trial 4Edwards Lifesciences Receives FDA Approval to Add Transapical Delivery System to U.S. Clinical Trial of Transcatheter Heart Valve 2Edwards Lifesciences Receives FDA Approval to Add Transapical Delivery System to U.S. Clinical Trial of Transcatheter Heart Valve 3Techne Corporation Releases Unaudited Second Quarter Results for Fiscal Year 2008 2Techne Corporation Releases Unaudited Second Quarter Results for Fiscal Year 2008 3Techne Corporation Releases Unaudited Second Quarter Results for Fiscal Year 2008 4Techne Corporation Releases Unaudited Second Quarter Results for Fiscal Year 2008 5Techne Corporation Releases Unaudited Second Quarter Results for Fiscal Year 2008 6Techne Corporation Releases Unaudited Second Quarter Results for Fiscal Year 2008 7
(Date:4/27/2015)... 27, 2015  For more than four decades, AUVSI,s ... been the premier worldwide event for the unmanned land, ... must-attend event for any local, national, or trade news ... commercial markets and current applications of unmanned technologies. The ... projected $48 billion industry, and how it will soon ...
(Date:4/20/2015)... , April 20, 2015 ...   Glenbeigh Records Management (GRM), Ireland,s ... with Dubai Islamic Bank. Having built up an impressive track ... now a leading player within the records management sector in ... expects to double is GCC staffbase and employ a further ...
(Date:4/13/2015)... CHICAGO , April 13, 2015  higi, a ... with ways to more fully engage with their communities ... its industry-leading, privacy protected and secure API.  ... API enables the most accessible, affordable, and convenient vehicle ... The API will ...
Breaking Biology News(10 mins):UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3
... CLEMSON The National Science Foundation (NSF) has awarded ... Engineering (CBIOE) at Clemson University for the development of ... causes, progression and treatment of breast cancer. The ... based on inkjet printing and will allow the creation ...
... Over the last forty years, Shigetada Nakanishi has unraveled ... the human nervous system. His work has created ... Today at 2.30 pm he will receive the Gruber ... Diego. In the 2007 Gruber Lecture he will ...
... the Journal of Proteome Research, authored by researchers ... Rosetta Inpharmatics LLC, CXR Biosciences Ltd, the Cancer ... and enhanced analytic power of the combination of ... microarray analysis methods of Genomatix Software GmbH., The ...
Cached Biology News:Breast cancer research and inkjet tissue printing get NSF boost 2Shigetada Nakanishi receives $500,000 Gruber Neuroscience Prize 2
Applications include ELISA, immunochemistry, and Western blotting. Working Concentrations: ELISA: 0.005-0.05 U/ml, immunohisto/cytochemistry: 0.25-0.5 U/ml, Western blot: 0.1-0.25 U/ml....
...
Recombinant Ovine IFN Tau. Active on sheep, cow, human and mouse cells. Activity: 5.7 x 10 7 u/mg...
... Thermo's Wellwash AC is the easiest ... and is provided with liquid level ... bottles. The integrated orbital shaker and ... excellent washing performance. The big bottle ...
Biology Products: